CY1111630T1 - Παραγωγα κυτοκινων - Google Patents

Παραγωγα κυτοκινων

Info

Publication number
CY1111630T1
CY1111630T1 CY20111100216T CY111100216T CY1111630T1 CY 1111630 T1 CY1111630 T1 CY 1111630T1 CY 20111100216 T CY20111100216 T CY 20111100216T CY 111100216 T CY111100216 T CY 111100216T CY 1111630 T1 CY1111630 T1 CY 1111630T1
Authority
CY
Cyprus
Prior art keywords
producers
cycling
terminal portion
polypeptides
seq
Prior art date
Application number
CY20111100216T
Other languages
English (en)
Inventor
Oliver Hartley
Original Assignee
Mintaka Foundation For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mintaka Foundation For Medical Research filed Critical Mintaka Foundation For Medical Research
Publication of CY1111630T1 publication Critical patent/CY1111630T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

Η εφεύρεση αναφέρεται σε πολυπεπτίδια που περιλαμβάνουν ένα τμήμα Ν-τερματικού άκρου και ένα τμήμα C-τερματικού άκρου όπου το εν λόγω τμήμα του Ν-τερματικού άκρου περιλαμβάνει την αλληλουχία-υπογραφή QGP[P ή L] και η αλληλουχία αμινοξέων του εν λόγω τμήματος του C-τερματικού άκρου είναι τουλάχιστον κατά 70% ταυτόσημη με την ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 1, και σε χρήσεις αυτών.
CY20111100216T 2006-07-25 2011-02-23 Παραγωγα κυτοκινων CY1111630T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
EP07825334A EP2076532B1 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
CY1111630T1 true CY1111630T1 (el) 2015-10-07

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100216T CY1111630T1 (el) 2006-07-25 2011-02-23 Παραγωγα κυτοκινων

Country Status (26)

Country Link
US (2) US8686111B2 (el)
EP (1) EP2076532B1 (el)
JP (1) JP5224603B2 (el)
KR (1) KR101530353B1 (el)
CN (1) CN101511867B (el)
AT (1) ATE490270T1 (el)
AU (1) AU2007278894B2 (el)
BR (1) BRPI0715331B8 (el)
CA (1) CA2658806C (el)
CY (1) CY1111630T1 (el)
DE (1) DE602007010969D1 (el)
DK (1) DK2076532T3 (el)
ES (1) ES2361455T3 (el)
GB (1) GB0614755D0 (el)
HK (1) HK1131162A1 (el)
HR (1) HRP20110146T1 (el)
ME (1) ME01320B (el)
MX (1) MX2009000918A (el)
NZ (1) NZ575092A (el)
PL (1) PL2076532T3 (el)
PT (1) PT2076532E (el)
RS (1) RS51854B (el)
RU (1) RU2461567C2 (el)
SI (1) SI2076532T1 (el)
WO (1) WO2008012689A2 (el)
ZA (1) ZA200901342B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
MX2020012782A (es) 2018-05-28 2021-04-28 ORION Biotechnology Switzerland Sarl Inhibidor de ccr5 para el uso en el tratamiento de cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
CN101511867B (zh) 2014-04-09
BRPI0715331B1 (pt) 2021-04-13
ZA200901342B (en) 2010-11-24
JP2009544304A (ja) 2009-12-17
US8686111B2 (en) 2014-04-01
HK1131162A1 (en) 2010-01-15
ATE490270T1 (de) 2010-12-15
US9328153B2 (en) 2016-05-03
CA2658806A1 (en) 2008-01-31
EP2076532B1 (en) 2010-12-01
CN101511867A (zh) 2009-08-19
JP5224603B2 (ja) 2013-07-03
WO2008012689A3 (en) 2008-05-08
RU2461567C2 (ru) 2012-09-20
PT2076532E (pt) 2011-03-02
EP2076532A2 (en) 2009-07-08
US20130330305A1 (en) 2013-12-12
DE602007010969D1 (de) 2011-01-13
KR101530353B1 (ko) 2015-06-26
AU2007278894B2 (en) 2012-08-09
AU2007278894A1 (en) 2008-01-31
US20090317363A1 (en) 2009-12-24
ME01320B (me) 2013-12-20
HRP20110146T1 (hr) 2011-06-30
MX2009000918A (es) 2009-08-26
GB0614755D0 (en) 2006-09-06
BRPI0715331B8 (pt) 2021-05-25
WO2008012689A2 (en) 2008-01-31
PL2076532T3 (pl) 2011-07-29
BRPI0715331A2 (pt) 2013-07-16
ES2361455T3 (es) 2011-06-17
CA2658806C (en) 2017-01-03
SI2076532T1 (sl) 2011-06-30
RS51854B (en) 2012-02-29
KR20090060281A (ko) 2009-06-11
DK2076532T3 (da) 2011-03-07
NZ575092A (en) 2011-08-26
RU2009106436A (ru) 2010-08-27

Similar Documents

Publication Publication Date Title
NZ600731A (en) Oxyntomodulin peptide analogue
IN2014CN02050A (el)
NZ600690A (en) Fkbp-l and uses thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
ATE417595T1 (de) Keratin-bindende polypeptide
MX2008009493A (es) Peptido novedoso y uso del mismo.
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
NZ591612A (en) Prevention, treatment and diagnosis of p.gingivalis infection with peptides
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
DE602007004110D1 (de) Hausstaubmilbenallergen
WO2008113536A8 (en) Neurotrophic peptides
WO2007142582A8 (en) Fluorescent proteins and genes encoding them
WO2010057242A3 (de) Vakzin
CY1111630T1 (el) Παραγωγα κυτοκινων
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
DE602005016417D1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
MY150639A (en) T cell adhesion molecule and antibody thereto
WO2006123157A3 (en) Nematistatic protein
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung